Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sumatriptan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Sumatriptan. Displaying page 1 of 1.
    EudraCT Number: 2007-002435-93 Sponsor Protocol Number: UNITHER/UN/07/001 Start Date*: 2007-09-20
    Sponsor Name:UNITHER PHARMACEUTICALS
    Full Title: Evaluation d'une solution hydro-alcoolique de sumatriptan administrée par voie sublinguale dans le traitement d'une crise d'algie vasculaire de la face, à la dose de 2mg, 4mg ou 6mg déterminée par ...
    Medical condition: Cluster headaches
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002654-36 Sponsor Protocol Number: Zomig nasal 5mg/Imigran novum 100mg Start Date*: 2007-10-08
    Sponsor Name:Carl Dahlöf
    Full Title: A randomised prospective open multi-attack study of patient preference and efficacy between zolmitriptan nasal spray 5 mg and sumatriptan RDT 100 mg in the acute treatment of migraine.
    Medical condition: Migraine with and without aura (G 43.0 and G 43.1)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002677-41 Sponsor Protocol Number: KA20060069 Start Date*: 2006-07-21
    Sponsor Name:Danishy Headache Center, KAS Glostrup, Dep. N01
    Full Title: Neuropeptides in the human intra - and extracerebral circulation - before and after affecting the trigeminovascular system with sumatriptan in healthy volunteers.
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005991-41 Sponsor Protocol Number: OPTUK MSPP PRO002 Start Date*: 2007-03-12
    Sponsor Name:OptiNose UK Ltd.
    Full Title: A multicentre, double-blind, placebo-controlled evaluation of intranasal sumatriptan delivered with the OptiNose powder device in the treatment of acute migraine.
    Medical condition: Acute Treatment of Migraine with or without Aura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005256-34 Sponsor Protocol Number: 38589 Start Date*: 2012-10-29
    Sponsor Name:Erasmus MC
    Full Title: Sumatriptan non-responders: evaluation of a possible biomarker
    Medical condition: Healthy Volunteers (Migraine)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004880-35 Sponsor Protocol Number: SUM111035 Start Date*: 2016-12-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022055-36 Sponsor Protocol Number: S52478 Start Date*: 2010-10-04
    Sponsor Name:UZLeuven
    Full Title: Intragastric pressure as a determinant of satiation.
    Medical condition: healthy volunteers no medical condition; drugs will be studies because they are known to influence gastric motility.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019083-36 Sponsor Protocol Number: PARACAF-emi-010 Start Date*: 2010-07-27
    Sponsor Name:U.O. Tossicologia
    Full Title: Evaluation of the effectiveness and the tollerability of paracetamol 1000 mgs + caffeine 130 mgs in the treatment of the migraine. I study randomizzato, double blind, double dummy, vs. sumatriptan ...
    Medical condition: Patients will be enlisted you cut from migraine with and without aura (codes 1.1 and 1.2.1, according to the criterions defined by the International Classification ICH2 of the 2004)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019231 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002737-39 Sponsor Protocol Number: Start Date*: 2005-06-14
    Sponsor Name:National Headache Institute
    Full Title: Prophylactic treatment of episodic cluster headache with an angiotensin II receptor blocker (candesartan cilexetil); a randomized, placebo controlled parallel study.
    Medical condition: Episodic cluster headache
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019058-42 Sponsor Protocol Number: LITIO-SUM-FC-002 Start Date*: 2010-05-26
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: Safety of sumatriptan in combination with lithium for treatment of cluster headache, Pilot Study,Phase II
    Medical condition: Cluster Headache
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019232 Headaches cluster LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005392-10 Sponsor Protocol Number: CBGG492A2204 Start Date*: 2009-03-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of si...
    Medical condition: Acute migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066635 Acute migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001260-29 Sponsor Protocol Number: CCH01 Start Date*: 2019-09-10
    Sponsor Name:CCH Pharmaceuticals
    Full Title: Proof of concept study for evaluation of the effect of ketamine intranasal spray in treatment of chronic Cluster Headache (CCH)
    Medical condition: Chronic Cluster Headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006687-25 Sponsor Protocol Number: 79665 Start Date*: 2022-07-21
    Sponsor Name:Leiden University Medical Centre
    Full Title: Repeated corticosteroid injections around the Greater Occipital Nerve (GON) as prophylactic treatment in chronic cluster headache
    Medical condition: Chronic Cluster headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003604-14 Sponsor Protocol Number: RBHP-2020-MOISSET Start Date*: 2021-03-11
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title: Evaluation of the efficacy of a single infusion of ketamine combined with magnesium sulfate to treat refractory chronic cluster headache
    Medical condition: Refractory chronic cluster headache
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000209-25 Sponsor Protocol Number: 69HCL20_1158 Start Date*: 2021-09-17
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Exploration de la physiopathologie de l’Algie Vasculaire de la Face (AVF) en TEP-IRM à l’aide du [18F]F13640 F13640-AVF
    Medical condition: Algie Vasculaire de la Face
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    Population Age: Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003646-33 Sponsor Protocol Number: 20190008 Start Date*: 2020-06-24
    Sponsor Name:Amgen, Inc.
    Full Title: Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Ph...
    Medical condition: High frequency episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) PT (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-004109-28 Sponsor Protocol Number: GA1211 Start Date*: 2013-01-18
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A randomised, 4 way crossover, double blind, placebo controlled pilot study in patients with reflux symptoms, to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Mint ’ us...
    Medical condition: This study assesses suppression of gastro-oesophageal reflux of Gaviscon in patients with gastro-oesophageal reflux disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:10:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA